Acceptance based on objective response rate data from the Phase 2 LITESPARK-015 trial evaluating WELIREG in certain patients with advanced PPGL If approved, WELIREG would be the only available therapy ...

The FDA has granted Priority Review to Merck's supplemental new drug application (sNDA ... or metastatic pheochromocytoma and paraganglioma (PPGL). According to the company, the sNDA is supported by ...

Kyle Walcott, 44, of Harrisburg, allegedly submitted 16 fraudulent fire service training certificates—purportedly from the University of Maryland Fire and Rescue Institute—to both the Paxtang Fire ...

Witnesses Sought In Crash Killing MD Twin, 20, As Suspect Flees Scene: PA State Police Pennsylvania State Police ... The crash happened on the Susquehanna Trail South in Springfield Township, York ...

Analysts expected earnings of $1.61 per share on $15.48 billion in revenue. Shares of Merck & Co. Inc. tumbled nearly 10%, or $9.64, to $90.15 at the opening bell Tuesday.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $112.46, a high ...

LOS ANGELES, CA / ACCESS Newswire / February 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of ...

Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new ...

Robert Davis; Chairman of the Board, President, Chief Executive Officer; Merck & Co Inc Caroline Litchfield; Chief Financial Officer, Executive Vice President; Merck & Co Inc Dean Li; Executive ...

The latest example of this trend is Merck KGaA’s impending all-cash acquisition of SpringWorks Therapeutics, valued around ...

The suit alleges defendants issued false statements concerning Merck business and prospects, resulting in its stock trading at inflated prices.

Robert Davis; Chairman of the Board, President, Chief Executive Officer; Merck & Co Inc Caroline Litchfield; Chief Financial Officer, Executive Vice President; Merck & Co Inc Dean Li; Executive Vice ...